GLP-1 Therapies Gain Momentum Among the most closely watched developments is the expanding role of glucagon-like peptide-1 (GLP-1) receptor agonists in Although initially developed for type 2 Investigators have pointed to reductions in inflammation, weight burden, and cardiometabolic stress as potential mechanisms driving improved functional outcomes
7 It is also a prebiotic that feeds beneficial gut bacteria
In particular, they have shown a reduction of major adverse cardiovascular events (MACE) in diabetic patients at high cardiovascular risk [23,24,25,26,27,28,29,30]
This hormone signals your brain to stop eating, slows down how fast food leaves your stomach, and improves how your body handles insulin
Contact PlexusDx or your provider immediately for a replacement
However, Roches therapy demonstrated promise not only for achieving weight loss but in pre-diabetes too